Skip to main content
Erschienen in: Journal of Translational Medicine 1/2010

Open Access 01.12.2010 | Research

Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study

verfasst von: Shunsaku Takahashi, Norimasa Miura, Tomomi Harada, ZhongZhi Wang, Xinhui Wang, Hideyuki Tsubokura, Yoshiaki Oshima, Junichi Hasegawa, Yoshimi Inagaki, Goshi Shiota

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2010

Abstract

Background

We previously reported that measuring circulating serum mRNAs using quantitative one-step real-time RT-PCR was clinically useful for detecting malignancies and determining prognosis. The aim of our study was to find crucial serum mRNA biomarkers in esophageal cancer that would provide prognostic information for post-esophagectomy patients in the critical care setting.

Methods

We measured serum mRNA levels of 11 inflammatory-related genes in 27 post-esophagectomy patients admitted to the intensive care unit (ICU). We tracked these levels chronologically, perioperatively and postoperatively, until the two-week mark, investigating their clinical and prognostic significance as compared with clinical parameters. Furthermore, we investigated whether gene expression can accurately predict clinical outcome and prognosis.

Results

Circulating mRNAs in postoperative esophagectomy patients had gene-specific expression profiles that varied with the clinical phase of their treatment. Multivariate regression analysis showed that upregulation of IL-6, VWF and TGF-β1 mRNA in the intraoperative phase (p = 0.016, 0.0021 and 0.009) and NAMPT and MUC1 mRNA on postoperative day 3 (p < 0.01) were independent factors of mortality in the first year of follow-up. Duration of ventilator dependence (DVD) and ICU stay were independent factors of poor prognosis (p < 0.05). Therapeutic use of Sivelestat (Elaspol®, Ono Pharmaceutical Co., Ltd.) significantly correlated with MUC1 and NAMPT mRNA expression (p = 0.048 and 0.045). IL-6 mRNA correlated with hypercytokinemia and recovery from hypercytokinemia (sensitivity 80.9%) and was a significant biomarker in predicting the onset of severe inflammatory diseases.

Conclusion

Chronological tracking of postoperative mRNA levels of inflammatory-related genes in esophageal cancer patients may facilitate early institution of pharamacologic therapy, prediction of treatment response, and prognostication during ICU management in the perioperative period.
Begleitmaterial
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1479-5876-8-103) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ST and MN designed experiments, interpreted data and drafted the manuscript; TH and HT managed patient samples, prepared RNA; ZW and XW performed real-time PCR; YO, JH, YI and GS provided detailed ideas and discussions.
All authors have read and approved the final manuscript.
Abkürzungen
ICU
intensive care unit
MMP9
matrix metallopeptidase 9
CRP
C reactive protein
EGR1
early growth response 1
HMGB1
high-mobility group box 1
MUC1
mucin 1
NAMPT (PBEF1)
nicotinamide phosphoribosyltransferase
PDGFA
platelet-derived growth factor alpha polypeptide
TGF-β1
transforming growth factor beta 1
TNF-α
tumor necrosis factor-alpha
VWF
von Willebrand factor
ARDS
acute respiratory distress syndrome
SIRS
systemic inflammatory response syndrome
SNISIRS
severe non-infectious systemic inflammatory response syndrome
GE
gene expression
SOFA score
sequential organ failure assessment score
SS
severe sepsis
DVD
duration of ventilator dependence
CRAS
circulating ribonucleic acids in serum
ALI
acute lung injury
PMX
polymyxin B-immobilized fiber column
MUC1
mucin 1
IL-6
interleukin-6
ECM
extracellular matrix
NAD
nicotinamide adenine dinucleotide
SCF
SKP1-CUL1-F.

Background

Esophageal cancer is one of the most aggressive malignant tumors of the digestive tract. Post-esophagectomy anastomotic leak and pneumonia are common and can lead to acute respiratory distress syndrome (ARDS). Acute respiratory distress syndrome (ARDS) is a diffuse heterogeneous lung disease resulting in progressive hypoxemia due to ventilation/perfusion mismatching and intrapulmonary shunting. Its causes are diverse and it is associated with a near 100% mortality after 48 hours [1, 2]. Ventilator-induced acute lung injury (ALI) is known to cause diffuse parenchymal damage secondary to alveolar overdistension, bacterial translocation and cytokine release [3, 4]. Detailed, sequential assessment of organ dysfunction during the first 48 hours of ICU admission is a reliable indicator of prognosis [5].
Recently, the use of gene-expression profiling on a transcriptome level of peripheral blood mononuclear cells (PBMC) identifies signature genes that distinguish severe sepsis (SS) from noninfectious causes of systemic inflammatory response syndrome (SIRS), sepsis-related immunosuppression and reduced inflammatory response [6]. SS has been categorized as a subset of SIRS resulting from hypercytokinemia [7]. As there are currently no reliable genetic markers for use in ICU care and prognostication, we aimed to determine the clinical value of measuring circulating RNA in the serum of ICU patients [8]. Since circulating RNA remains stable for approximately 24 hours, its detection may reflect early changes in clinical status and may make it possible to predict morbidity and survival [9].
We previously reported that the measurement of human telomerase reverse transcriptase gene (hTERT) mRNA in serum is useful for the diagnosis of some malignancies. We also found that serum transforming growth factor-α mRNA is useful as a prognostic indicator in fulminant hepatitis in patients without encephalopathy upon admission [10, 11]. In the present study, we examined 11 proinflammatory genes in patients receiving therapy in the ICU following surgery for esophageal cancer: matrix metallopeptidase 9 (MMP9), which reflects the activity of neutrophils and correlates with survival in patients with esophageal cancer [1214]; early growth response 1 (EGR1), as a transcriptional regulator in ALI [1517]; high-mobility group box 1 (HMGB1), as a candidate proinflammatory factor predicting the prognosis of SIRS [1820]; mucin1 (MUC1), as both an independent predictor for intravascular coagulation in ARDS and a biomarker for esophageal cancer [2123]; nicotinamide phosphoribosyltransferase (NAMPT/PBEF1), as a regulator in new inflammatory networks [2427]; platelet-derived growth factor alpha polypeptide (PDGFA), which is involved in alveolar septal formation [2830]; transforming growth factor beta 1 (TGF-β1), as an activator of procollagen I in patients with acute lung injury (ALI) [3133]; tumor necrosis factor-alpha (TNF-α), as a prognostic determinant of ARDS in adults [3436]; von Willebrand factor (VWF), as an independent marker of poor outcome in patients with early ALI [3739]; and interleukin 6 (IL-6), which is upregulated in inflammation and promotes the maturation of B cells [40]. Lung injury-related genes (HMGB1, MUC1 and VWF), proinflammation-related genes (MMP, CRP, and HMGB1), coagulation-related genes, immunoreactive genes (PBEF1 and TNF-α), fibrosis-related gene (TGF-β), wound-healing related gene (PDGFA), and cancer-related genes (MUC1 and hTERT) have been reported previously to correlate with the onset of ARDS or SIRS and subsequent survival. ARDS and SIRS seriously affect the prognosis of postoperative patients. Anastomotic leak and pneumonia extend the length of ICU stay and duration of ventilator dependence, resulting in a poorer prognosis. We investigated the clinical significance and prognostic usefulness of measuring serum levels of mRNA of these genes chronologically from ICU admission in patients treated surgically for esophageal cancer.

Methods

Patients and sample collection

27 patients who underwent radical surgery for esophageal cancer at Tottori University Hospital, Tottori Red Cross Hospital and Shimane Prefectural Central Hospital, between January 2006 and December 2008, were prospectively studied (Tables 1, 2). All patients were admitted to the ICU after operation as per our department / Tottori University protocol. The patients were discharged from the ICU when stable according our critical care departmental criteria.
Table 1
Patient Demographics in ICU After Surgical Treatment of Esophageal Cancer
Pt.#
*Con/Siv
DVD
ICU stay
Operation time
Anesthesia time
PaO2/FiO2 ratio (POD1)
SIRS
SOFA scores (POD1)
Anastomotic Leak
Pneumonia
Mortality (-30D)
Mortality (-6M)
Mortality (-1Y)
#1
Siv
2
3
765
856
211.3
2
3
+(POD8)
-
alive
alive
dead
#2
Siv
2
2
510
560
272.5
6
5
-
+(POD3)
alive
alive
dead
#3
Con
0
2
270
343
125
1
4
-
-
alive
alive
alive
#4
Siv
2
2
555
638
148.8
0
3
+(POD5)
-
alive
alive
alive
#5
Con
2
6
233
370
220
0
7
-
-
alive
alive
alive
#6
Con
7
6
930
1025
302.5
4
5
+(POD9)
+(POD7)
alive
alive
alive
#7
Siv
2
3
525
565
148
2
4
+(POD5)
-
alive
alive
alive
#8
Con
0
4
285
400
246
1
2
-
-
alive
alive
alive
#9
Siv
2
12
467
580
206
5
5
+(POD6)
-
alive
alive
alive
#10
Con
2
3
681
573
194.3
8
5
+(POD5)
-
alive
alive
dead
#11
Siv
74
74
615
682
190
31
6
+(POD5)
+(POD2)
alive
dead
dead
#12
Con
2
3
491
598
184
2
6
-
-
alive
alive
alive
#13
Con
2
3
487
570
212
1
3
+(POD5)
-
alive
alive
alive
#14
Con
6
7
543
630
447.5
7
2
-
+(POD3)
alive
alive
alive
#15
Siv
0
0
415
505
213.8
3
2
-
-
alive
alive
alive
#16
Siv
3
16
551
695
272.2
1
6
+(POD5)
-
dead
dead
dead
#17
Con
2
3
645
715
244
7
5
+(POD7)
-
alive
alive
alive
#18
Siv
11
13
547
602
277.5
2
4
-
-
alive
alive
alive
#19
Siv
3
4
520
564
342.5
1
4
-
-
alive
alive
alive
#20
Siv
3
4
698
775
397.5
1
6
+(POD12)
+(POD3)
alive
alive
alive
#21
Con
6
7
657
760
360
3
4
-
+(POD6)
alive
alive
alive
#22
Siv
4
6
1305
1375
187.5
1
9
-
-
alive
alive
alive
#23
Con
2
3
735
820
257
5
2
-
+(POD7)
alive
alive
alive
#24
Con
3
8
724
795
252
2
5
-
-
alive
alive
alive
#25
Con
1
5
525
580
216
1
2
+(POD5)
-
alive
alive
alive
#26
Con
5
7
254
345
245
0
5
-
-
alive
alive
alive
#27
Siv
3
8
572
629
257.5
5
6
-
+(POD4)
alive
alive
alive
Pt #: patient number, * con: conventional therapy, Siv: Sivelestat. DVD; duration of ventilator dependence
Table 2
Gene Expression Data for Esophageal Cancer Patients in the ICU After POD 14
Pt.#
SCC
(ng/mL)
Cytokeratin fragment 19
(ng/mL)
CEA
(ng/mL)
hTERTmRNA
(logarithmic copy number)
Recurrence
Depth of tumor
invasion
#1
2.4
2.5
-
3.31
-
Mp
#2
-
-
-
3.9
-
Sm
#3
0.9
1.5
-
2.96
+
Ss
#4
< 0.5
1.4
-
4.41
-
Sm
#5
-
-
-
0
-
M
#6
2.0
1.6
-
0
+
Ss
#7
0.9
0.9
-
4.96
-
Sm
#8
< 0.5
1.9
-
0
-
Ss
#9
1.1
1.3
3.8
2.97
-
Ss
#10
1.2
2.1
1.0
3.58
-
Ss
#11
-
-
-
2.75
-
Ss
#12
0.8
0.9
-
2.14
-
Ss
#13
1.6
2.7
1.4
4.61
-
Sm
#14
2.7
-
3.1
3.99
-
Ss
#15
0.9
3.0
-
3.84
-
Ss
#16
-
-
-
3.81
-
Sm
#17
1.6
7.4
-
4.14
-
Mp
#18
1.3
0.9
2.4
4.53
-
Sm
#19
0.7
2.5
-
4.11
-
Sm
#20
3.9
3.1
2.4
4.41
-
Ss
#21
2.9
-
3.5
3.44
-
Mp
#22
0.7
2.2
-
4.35
-
Sm
#23
< 0.5
1.4
-
4.03
-
Ss
#24
1.4
-
-
3.89
-
M
#25
1.2
1.4
-
3.35
-
Ss
#26
-
-
-
4.39
-
M
#27
0.7
0.9
2.3
4.45
-
Mp
-: not measured
We measured serum mRNA levels for 14 days postoperatively. Informed consent was obtained from each patient and study protocols followed standard ethical guidelines (Declaration of Helsinki, 1975) and were approved by the institutional review board of Tottori University (approval no.138, no 138 1, 2001; no. 343, 2009). The patients consisted of 3 females (mean age 67.3 years, age range 49 to 82 years) and 24 males (mean age 65 years, age range 40-76). All patients were classified as American Society of Anesthesiologists (ASA) physical status 1 or 2. Patients were prospectively followed for 12 months postoperatively. SIRS or ARDS were diagnosed according to accepted consensus definitions [41, 42]. Clinicopathological findings, such as age, diagnosis, etiology, prognosis, effect of the neutrophil elastase inhibitor sivelestat (4.8 mg/kg/day), total days of ventilator dependence (DVD), total days of ICU stay, preoperative CRP levels (preCRP), CRP levels at postoperative day (POD) 1, peak concentrations of CRP (peak CRP), operation duration, anesthesia duration, PaO2/FiO2 ratio at POD 1, days of SIRS, sequential organ failure assessment (SOFA) scores at POD 1, and mortality at 30 days, 6 months, and 1 year were recorded.
Anesthesia consisted of general anesthesia and epidural anesthesia. After surgery, all patients were reintubated with single-lumen endotracheal tubes from the double-lumen endotracheal tubes used intraoperatively and received ventilator support in ICU. Serum from whole blood was obtained intraoperatively and on POD 1, POD 3, POD 5 and POD 14. We measured serum mRNA levels of 11 genes (MMP9, CRP, HMGB1, MUC1, EGR1, PBEF1, PDGFA, TGF-β1, TNF-α, VWF, and IL-6). Sivelestat was prophylactically administered intravenously by the judgment of the attending physician and according to the manufacturer's recommendations. We distinguished SIRS from severe non-infectious systemic inflammatory response syndrome (SNISIRS) by examining gene expression (GE) in the serum and synchronizing GE changes with the clinical course of events.
Processing of the blood and serum samples was performed after blood sampling during the operation and at POD 1, POD 3, POD 5 and POD 14. mRNA quantification was performed as previously described [43]. RNA extraction and real-time RT-PCR RNA was performed after DNase treatment, also reported previously [4345]. In brief, RNA from 200 μl of serum was dissolved in 200 μl of H2O. RT-PCR was performed using 1 μl of RNA extract and 2 μl of SYBR Green I (Roche, Basel, Switzerland) in a one-step RT-PCR kit (Qiagen, Tokyo, Japan). RNA was extracted from blood using the same volume of serum concentrated 20-fold (Invitrogen Corp., Carlsbad, CA, USA). RT-PCR conditions were: incubation at 50°C for 30 min followed by incubation for 12 min at 95°C for denaturation, then 50 cycles at 95°C (0 s), annealing at 50-55°C (10 s) and 72°C (15 s), and extension at 40°C (20 s). All primers were optimally designed (INTEC Web & Genome Informatics Corp., Tokyo, Japan). The final concentration of the primers was 1 μM; sequences are shown in Table 3. The dynamic range of the real-time PCR analysis for each mRNA was more than 5-10 copies in this assay, but we semi-quantitatively measured 11 gene expression profiles of interest as relative expression levels against β-actin mRNA [46]. The RT-PCR assay was repeated twice and quantification was reproducibly confirmed with LineGene (TOYOBO, Tokyo, Japan). We confirmed that the amplicons were derived from the gene of interest by Western blot. IL-6 protein level was measured using an ELISA kit according to the manufacturer's instruction (R&D Systems, MN, USA). SOFA was scored according to international criteria [47].
Table 3
Primer Sets Used for Each Gene Investigated
Gene
GenBank Accession No.
Forward Primer
Reverse Primer
VWF
NM_000552.2
TGA CCA GGT TCT CCG AGG AG
CAC ACG TCG TAG CGG CAG TT
TGFB1
MN_000660.3
GAC TAC TAC GCC AAG GAG GT
GGA GCT CTG ATG TGT TGA AG
PDGFA
MN_002607.5
GGG AGT GAG GAT TCT TTG GA
AAA TGA CCG TCC TGG TCT TT
NAMPT
MN_005746.2
CTG TTC CTG AGG GCA TTG TC
GGC CAC TGT GAT TGG ATA CC
CRP
MN_000567.2
ACA GTG GGT GGG TCT GAA AT
TAC CCA GAA CTC CAC GAT CC
EGR1
MN_001964.2
TTC TTC GTC CTT TTG GTT TA
CTT AAG GCT AGA GGT GAG CA
HMBG1
MN_002128.4
AAC CAC CCA GAT GCT TCA GT
TCC GCT TTT GCC ATA TCT TC
TNF-α
MN_000594.2
TGC TTG TTC CTC AGC CTC TT
GCA CTC ACC TCT TCC CTC TG
MUC1
MN_001018016.1
CCA TTC CAC TCC ACT CAG GT
CCT CTG AAG GAG GCT GTG AT
MMP9
NM_004994.2
TTG ACA GCG ACA AGA AGT GG
CCC TCA GTC AAG CGC TAC AT
IL-6
MN_000600.3
ATG CAA TAA CCA CCC CTG AC
TAA AGC TGC GCA CAA TGA GA
β-actin
MN_031144.2
ACC TGA CTG ACT ACC TCA TG
GCA GCC GTG GCC ATC TCT TG

Statistical Analysis

Clinical parameters and gene expression profiles were statistically evaluated using SPSS 13.0 (SPSS Japan Inc., an IBM company, 2004). Multivariate regression analysis was performed with respect to prognosis weighted at 30 days, 6 months and 12 months or with stepwise selection. In addition, we tested the effects of sivelestat, polymyxin B-immobilized fiber column (PMX), and factors predicting the development anastomotic leak or pneumonia against clinical course and gene expression by one-way ANOVA. To assess the accuracy of the prognostic factors (medication use, gene function in the acute phase, and ventilatory regulation), the correlation of each factor with prognosis was evaluated using receiver operator characteristic (ROC) curve analyses. A predictive cut-off value was evaluated as the nearest point from the left upper edge of the ROC curve analysis graph. Sensitivity was calculated as the mean confidence interval (CI) of the area under the curve (AUC) and specificity was calculated in the output table of the ROC. To estimate survival, Kaplan-Meier analysis was performed. P values less than 0.05 were considered statistically significant.

Results

Circulating mRNA expression during hospitalization

The mRNA expression profiles over the 14 days are shown in Figure 1. MMP9 and NAMPT (PBEF1) were similar in that both were upregulated from POD 5 onwards. VWF and TGF-β1 demonstrated similar upregulation from POD 3. At POD 1, CRP mRNA upregulation was accompanied by increased serum CRP levels; these decreased at POD 3 following appropriate treatment (data not shown). MUC1 and PDGFA were upregulated at POD 3 (p = 0.048 and 0.045), followed by recovery from POD 5 to POD 14. IL-6 was upregulated at POD 5 then decreased to the intraoperative baseline value. EGR1 and HMGB1 levels gradually decreased from the intraoperative values to baseline at POD 14.
Two mRNAs of proinflammatory genes seen in ALI (HMGB1 and VWF) changed similarly (p = 0.021). CRP mRNA correlated with conventional CRP levels (p = 0.029 and 0.004). Primers designed for amplifying CRP mRNA did not detect inflammation with more sensitivity than conventional CRP. However, CRP mRNA correlated with CRP levels at PODs 1, 3, and 14 (p = 0.009, 0.02, and 0.009). Sensitivities and specificities of mRNA levels as prognostic indicators of clinical course are shown (Additional File 1). With respect to gene markers' association with surgical parameters, upregulation of TNF-α mRNA correlated with increased duration of anesthesia (p = 0.023); and VWF upregulation with increased duration of surgery (p = 0.025). MMP9 mRNA expression correlated with PDGFA mRNA up to POD 14 (p = 0.007) and treatment with sivelestat altered MUC1 expression (p = 0.024, Figure 2b). TNF-α mRNA expression correlated with duration of SIRS (p = 0.042). CRP mRNA expression correlated with length of ICU stay, which in turn was associated with 6-month mortality (p = 0.033 and 0.016).

Prognostic factors in the perioperative period

We found IL-6 mRNA to be a significant marker of prognosis (Figure 3b, c). IL-6 mRNA was upregulated in the immediate perioperative period (POD 0, Figure 3a) and gradually decreased at POD 3. Conversely, IL-6 levels increased postoperatively. The AUC of IL-6 mRNA and IL-6 was 0.809 and 0.453, respectively, and the predictive cut-off value of IL-6 mRNA was 3400 as a relative ratio to the β-actin copy number.
The stepwise analysis is shown in Table 4, suggesting that a high level of IL-6 mRNA at POD 0 is an independent indicator of poor prognosis (as are days of ventilator dependence, days of ICU stay, and days of SIRS (p < 0.0001); a high level at POD3 predicted the onset of pneumonia (p = 0.021). Days of ventilator dependence, days of ICU stay, and SIRS days were independent factors influencing prognosis (p < 0.05; data not shown). A significant reduction in mortality was seen by gene expression changes on POD 14 (p < 0.001 by one-way ANOVA). Upregulation of VWF and TGF-ß1 mRNA intraoperatively correlated with mortality (p = 0.0021 and 0.009). POD 1 upregulation of PDGFA, ERG1, and HMGB1 mRNA correlated significantly with worse prognosis. (p = 0.009, 0.004, and 0.012). At POD 3, NAMPT and MUC1 mRNA were found to be independent prognostic factors for 1-year mortality (p = 0.007, 0.012); at POD 14, NAMPT mRNA correlated with mortality at 30 days and 1 year (p < 0.0001 and p = 0.0016).
Table 4
Logistic Regression Analysis of Morbidity and Mortality With Stepwise Selection
 
gene
p value
R
 
gene
p value
R
 
gene
p value
R
DVD
   
1Y-mortality
   
6M-mortality
   
POD0
IL-6
< 0.0001
0.787
POD0
IL-6
0.016
0.69
POD0
VWF
< 0.0001
0.893
days of ICU stay
   
VWF
0.021
  
IL-6
< 0.0001
 
POD0
IL-6
< 0.0001
0.813
 
TGF-β1
0.009
 
30D-mortality
   
days of SIRS
   
POD1
PDGFA
0.009
0.71
POD0
VWF
< 0.0001
1.000
POD0
IL-6
< 0.0001
0.738
 
ERG1
0.004
  
NAMPT
< 0.0001
 
Pneumonia
    
HMGB1
0.012
 
POD5
HMGB1
< 0.0001
0.993
POD3
IL-6
0.021
0.442
POD3
NAMPT
0.007
0.63
 
MUC1
0.002
 
PaO 2 /FiO 2 ratio
   
MUC1
0.012
 
POD14
NAMPT
< 0.0001
1.000
POD1
MMP9
0.034
0.409
POD14
ERG1
0.0016
0.59
 
PDGFA
< 0.0001
 
SOFA score
    
NAMPT
0.0016
  
CRP
0.015
 
POD1
TGF-β1
0.005
0.528
        
N.A: no applicable; N.S.: not significant. R: correlation coefficient.
DVD: duration of ventilator dependence. Independence variables are MMP9, CRP (pre, POD1, peak), ERG, HMGB1, MUC1, PBEF, PDGFA, TGF-β1, TNF-α, VWF, IL-6, Sivelestat, PMX, anesthesia and operation time.
Sivelestat affected suppressive gene expression of CRP, EGR1, MUC1, TNF-α, PDGFA, NAMPT, and VWF (Table 5). However, PMX treatment did not improve clinical outcome (Figure 2b). The SOFA score correlated only with days of ventilator dependence and ICU stay (p = 0.038 and 0.039, Additional File 2).
Table 5
One-Way ANOVA Analysis With Respect to Sivelestat
Time course
Genetic parameters
P value
Contribution to prognosis
P value
POD 1
EGR1 mRNA
0.037
30D-mortality
0.032
 
MUC1 mRNA
0.041
6M-mortality
0.001
 
PDGFA mRNA
0.037
  
 
TNF-α mRNA
0.016
  
 
VWF mRNA
0.033
  
POD 3
CRP mRNA
0.023
6M-mortality
< 0.001
 
EGR1 mRNA
0.022
1Y-mortality
0.023
 
MUC1 mRNA
0.048
  
 
NAMPT mRNA
0.045
  
 
PDGFA mRNA
0.032
  
 
TGF-β1 mRNA
0.016
  
 
TNF-α mRNA
0.020
  
 
VWF mRNA
0.047
  
POD 5
CRP mRNA
0.001
30D-mortality
0.032
 
TNF-α mRNA
0.032
6M-mortality
0.001
POD 14
MMP9 mRNA
0.047
30D-mortality
0.032
 
EGR1 mRNA
0.034
6M-mortality
0.001
 
HMGB1 mRNA
0.042
  
 
NAMPT mRNA
0.032
  
 
TGF-β1 mRNA
0.048
  
 
VWF mRNA
0.032
  
12/27 (44%) patients experienced anastomotic leak (9 cervical and 3 thoracic, additional file 3). EGR1 and IL-6 mRNA expression correlated with anastomotic leak and pneumonia at POD 3 by regression analysis (p = 0.021, Table 4). Furthermore, increased duration of operation, anesthesia, and mechanical ventilation was associated with increased risk of pneumonia (p < 0.001, 0.028, and 0.022, Additional File 2, 4). PaO2/FiO2 ratio did not correlate with any other gene expressions.

Discussion

Esophageal cancer is one of the most aggressive malignant tumors of the digestive tract. Post-esophagectomy anastomotic leak and pneumonia are common; furthermore, they prolong ICU stay and contribute to poor prognosis [48]. It is of paramount importance to diagnose these complications immediately postoperatively, and treat them expeditiously [49].
We investigated gene expression by measuring circulating ribonucleic acids in serum (CRAS), with the hope of discovering early prognostic markers post-esophagectomy. We hypothesized that the expression of certain proinflammatory genes would predict outcome, and in particular that POD 1 levels would help to identify patients at risk for anastomotic leak and pneumonia. Furthermore, we expected that gene expression on POD 14 might predict mortality.
44% (33% cervical and 11% thoracic) of our patients experienced anastomotic leak, which was greater than that which is reported in the literature (expected less than 10%) [50]. Cervical leaks were treated conservatively while thoracic leaks were severe and contributed to the high morbidity rate as described in our study. We studied the correlation between mRNA levels and morbidity and mortality. Upregulation of VWF mRNA prognosticated poor clinical condition by multivariate analysis. Upregulation of EGR and NAMPT mRNA at POD 1, 3 and 14 indicates that we should become more clinically astute in the immediate postoperative period. The mean/median/cutoff values of IL-6 mRNA are 5906/2810/5900 and, in Kaplan-Meyer survival analysis; if they did not demonstrate significant value among clinical parameters, we concluded that IL-6 mRNA was not an indicative marker for outcome. However, they did correlate with duration of ventilator dependence and ICU stay (Figure 2).
Duration of ventilator dependence, duration of ICU stay and SIRS expectedly affected 6-month mortality, independent of cancer recurrence. Since these conditions are caused by the severity of the underlying disease, by unexpected immunoreactions, and by iatrogenic lung injury in the perioperative period, interpretation of their pathogenesis is complicated. Although the onset of SIRS is critical and can adversely affect recovery, we believe that serum gene expression profiles may reliably predict prognosis because of the mRNA stability; i.e., mRNA levels directly reflect pathophysiology either in real-time or over the past 24 hours.
The changes observed in gene expression was indicative of postoperative clinical course. CRP mRNA was upregulated first, with PDGFA, TNF-α and MUC1 mRNA following by POD 3. In turn, IL-6, VWF and TGF-β1 mRNA were upregulated at POD 5, then NAMPT, EGR1 and MMP9 mRNA. Thus, gene expression actively evolves after surgery for esophageal cancer. It remains unclear whether these changes occur in other disease states.
Four patients (#11, 13, 16, 20) received long-term sivelestat and displayed significant downregulation of NAMPT and MUC1 mRNA (p < 0.001 and 0.034 by one-way ANOVA) compared with the 23 patients who did not receive this medication. Four patients (#9, 11, 16, 20) with sepsis following anastomotic leak or aspiration pneumonia significantly upregulated the same genes (p < 0.001 and p = 0.025), if statistical analysis is weighted against dead outcome. As MUC1 expression correlated with CRP, NAMPT may be a crucial factor in the pro-inflammatory state.
Microarray analysis is inefficient for detecting small amounts of circulating RNA because of the limits of current biotechniques, particularly the requirement for at least 500 ml of blood. We chose candidate genes based on information from previous reports and examined their significance. We identified VWF and TGF-β1 as potential predictors of improved prognosis, the latter being an indicator of fibrosis. VWF is a glycoprotein that binds to coagulation factor VIII. It functions as both an antihemophilic factor and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to hemostasis and promotes adhesion of platelets to sites of vascular injury by forming a molecular bridge between the sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Therefore, upregulated VWF may represent unstable hemostasis and reflect damage to endothelial megakaryocytes expressing VWF. In the signaling pathway, VWF interacts with integrins in the extracellular matrix (ECM) and has functions in the complement and coagulation cascades, linking downstream to the inflammatory process or to B cell receptor signaling.
NAMPT is another indicator for prognosis. It is the rate-limiting component in the mammalian nicotinamide adenine dinucleotide (NAD) biosynthesis pathway, and promotes vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It was originally thought to be a cytokine that acted on early B-lineage precursor cells or T cell development, by enhancing the effect of IL-7 and SKP1-CUL1-F-box protein (SCF) on pre-B-cell colony formation. SCF mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. PDGFA is also a predictive factor for prognosis. It is activated in IFN-γ/IL-10 signaling in keratinocytes via the JAK/STAT pathway and is also involved in signaling via the MAPK cascades, STATs and NF-κB through its receptor. It contributes to balancing the Th1/Th2 switch by affecting anti-apoptosis and cell proliferation. EGR1 is targeted by Erk, is activated by IL-2 and IL-3 cascades, and targets eukaryotic translation initiation factor 4E binding protein 1. Severe inflammatory disease is a critical condition linked to collapse of the Th1/Th2 balance and, from a prognostic standpoint, these genes are upregulated when Th1 cells (producing IL-2, IL-3 and IFN-γ) are dominant over Th2 cells (generating IL-10 and leading to IL-7 activation). This suggests that novel therapeutic antibody drugs for SIRS may be found in the study of these cytokines.
TGF-α mRNA in serum has previously been described as a prognosticator in fulminant hepatitis [11] although this was not the case in our study. Expression of CRP mRNA correlated with the serum CRP level at all clinical phases, although we could not optimize the reaction condition for detecting CRP mRNA. We reconfirmed that CRP is an excellent marker for acute inflammation, but not for prognosis and SIRS onset. These prognostic genes for SIRS or sepsis may be useful in intensive care settings for earlier detection of decompensation [51].

Conclusion

We proposed measuring an inflammatory gene expression profile perioperatively in patients undergoing surgery for esophageal cancer. VWF and TGFB1 mRNA at POD 0 were prognostic biomarkers for mortality. IL-6 mRNA was a significant biomarker for the onset of severe inflammatory conditions and its upregulation throughout the postoperative period predicted poor prognosis. We could not distinguish SIRS from bacteremia. Further prospective studies on individual gene expression profiles are necessary to clarify their influence on prognosis in esophageal cancer.

Acknowledgements

This study was financially supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science. No conflicts of interest.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ST and MN designed experiments, interpreted data and drafted the manuscript; TH and HT managed patient samples, prepared RNA; ZW and XW performed real-time PCR; YO, JH, YI and GS provided detailed ideas and discussions.
All authors have read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Milberg JA, Davis DR, Steinberg KP: Improved survival of patients with acute respiratory distress syndrome: 1983-1993. JAMA. 1995, 273: 306-309. 10.1001/jama.273.4.306.PubMedCrossRef Milberg JA, Davis DR, Steinberg KP: Improved survival of patients with acute respiratory distress syndrome: 1983-1993. JAMA. 1995, 273: 306-309. 10.1001/jama.273.4.306.PubMedCrossRef
2.
Zurück zum Zitat Lewandowski K, Metz J, Deutschmann C: Incidence, severity, and mortality of acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995, 151: 1121-1125.PubMed Lewandowski K, Metz J, Deutschmann C: Incidence, severity, and mortality of acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995, 151: 1121-1125.PubMed
3.
Zurück zum Zitat Mink SN, Light RB, Cooligan T: Effect of PEEP on gas exchange and pulmonary perfusion in canine lobar pneumonia. J Appl Physiol. 1981, 50: 517-523.PubMed Mink SN, Light RB, Cooligan T: Effect of PEEP on gas exchange and pulmonary perfusion in canine lobar pneumonia. J Appl Physiol. 1981, 50: 517-523.PubMed
4.
Zurück zum Zitat Nahum A, Hoyt J, Schmitz L: Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med. 1997, 25: 1733-1743. 10.1097/00003246-199710000-00026.PubMedCrossRef Nahum A, Hoyt J, Schmitz L: Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med. 1997, 25: 1733-1743. 10.1097/00003246-199710000-00026.PubMedCrossRef
5.
Zurück zum Zitat Ferreira FL, Bota DP, Bross A: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001, 286: 1754-1758. 10.1001/jama.286.14.1754.PubMedCrossRef Ferreira FL, Bota DP, Bross A: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001, 286: 1754-1758. 10.1001/jama.286.14.1754.PubMedCrossRef
6.
Zurück zum Zitat Tang BM, McLean AS, Dawes IW: Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med. 2009, 37: 882-888. 10.1097/CCM.0b013e31819b52fd.PubMedCrossRef Tang BM, McLean AS, Dawes IW: Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med. 2009, 37: 882-888. 10.1097/CCM.0b013e31819b52fd.PubMedCrossRef
7.
Zurück zum Zitat Ulloa L, Tracey KJ: The "cytokine profile": a code for sepsis. Trends Mol Med. 2005, 11 (2): 56-63. 10.1016/j.molmed.2004.12.007.PubMedCrossRef Ulloa L, Tracey KJ: The "cytokine profile": a code for sepsis. Trends Mol Med. 2005, 11 (2): 56-63. 10.1016/j.molmed.2004.12.007.PubMedCrossRef
8.
Zurück zum Zitat Chen XQ, Bonnefoi H, Pelte MF: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000, 6: 3823-3826.PubMed Chen XQ, Bonnefoi H, Pelte MF: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000, 6: 3823-3826.PubMed
9.
Zurück zum Zitat Tsui NB, Ng EK, Lo YM: Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002, 48: 1647-1653.PubMed Tsui NB, Ng EK, Lo YM: Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002, 48: 1647-1653.PubMed
10.
Zurück zum Zitat Miura N, Hasegawa J, Shiota G: Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol. 2008, 2: 511-527.PubMedPubMedCentral Miura N, Hasegawa J, Shiota G: Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol. 2008, 2: 511-527.PubMedPubMedCentral
11.
Zurück zum Zitat Miura N, Kabashima H, Shimizu M: Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis. Hepatol Int. 2008, 2: 213-221. 10.1007/s12072-008-9053-6.PubMedPubMedCentralCrossRef Miura N, Kabashima H, Shimizu M: Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis. Hepatol Int. 2008, 2: 213-221. 10.1007/s12072-008-9053-6.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Wong FH, Huang CY, Su LJ: Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol. 2009, 34: 117-128.PubMed Wong FH, Huang CY, Su LJ: Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol. 2009, 34: 117-128.PubMed
13.
Zurück zum Zitat El-Kenawy Ael-M, Lotfy M, El-Kott A: Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content. J Clin Gastroenterol. 2005, 39: 791-794. 10.1097/01.mcg.0000177244.59591.c3.CrossRef El-Kenawy Ael-M, Lotfy M, El-Kott A: Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content. J Clin Gastroenterol. 2005, 39: 791-794. 10.1097/01.mcg.0000177244.59591.c3.CrossRef
14.
Zurück zum Zitat Gu ZD, Li JY, Li M, Gu J: Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005, 100: 1835-1843. 10.1111/j.1572-0241.2005.50018.x.PubMedCrossRef Gu ZD, Li JY, Li M, Gu J: Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005, 100: 1835-1843. 10.1111/j.1572-0241.2005.50018.x.PubMedCrossRef
15.
Zurück zum Zitat Ngiam N, Post M, Kavanagh BP: Early growth response factor-1 in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L1089-1091. 10.1152/ajplung.00265.2007.PubMedCrossRef Ngiam N, Post M, Kavanagh BP: Early growth response factor-1 in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L1089-1091. 10.1152/ajplung.00265.2007.PubMedCrossRef
16.
Zurück zum Zitat Hoetzel A, Dolinay T, Vallbracht S: Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med. 2008, 177: 1223-32. 10.1164/rccm.200708-1265OC.PubMedPubMedCentralCrossRef Hoetzel A, Dolinay T, Vallbracht S: Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med. 2008, 177: 1223-32. 10.1164/rccm.200708-1265OC.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Ingram JL, Antao-Menezes A, Mangum JB: Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. J Immunol. 2006, 177: 4141-4148.PubMedCrossRef Ingram JL, Antao-Menezes A, Mangum JB: Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. J Immunol. 2006, 177: 4141-4148.PubMedCrossRef
18.
Zurück zum Zitat El Gazzar M, Yoza BK, Chen X: Chromatin-specific remodeling by HMGB1 and linker histone H1 silence proinflammatory genes during endotoxin tolerance. Mol Cell Biol. 2009, El Gazzar M, Yoza BK, Chen X: Chromatin-specific remodeling by HMGB1 and linker histone H1 silence proinflammatory genes during endotoxin tolerance. Mol Cell Biol. 2009,
19.
Zurück zum Zitat Kornblit B, Munthe-Fog L, Madsen HO: Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care. 2008, 12: R83-10.1186/cc6935.PubMedPubMedCentralCrossRef Kornblit B, Munthe-Fog L, Madsen HO: Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care. 2008, 12: R83-10.1186/cc6935.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Suda K, Kitagawa Y, Ozawa S: Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery?. Dis Esophagus. 2006, 19: 5-9. 10.1111/j.1442-2050.2006.00529.x.PubMedCrossRef Suda K, Kitagawa Y, Ozawa S: Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery?. Dis Esophagus. 2006, 19: 5-9. 10.1111/j.1442-2050.2006.00529.x.PubMedCrossRef
21.
Zurück zum Zitat Nakashima T, Yokoyama A, Ohnishi H: Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med. 2008, 263: 432-439. 10.1111/j.1365-2796.2008.01929.x.PubMedCrossRef Nakashima T, Yokoyama A, Ohnishi H: Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med. 2008, 263: 432-439. 10.1111/j.1365-2796.2008.01929.x.PubMedCrossRef
22.
Zurück zum Zitat Sato H, Callister ME, Mumby S: KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004, 23: 142-145. 10.1183/09031936.03.00070303.PubMedCrossRef Sato H, Callister ME, Mumby S: KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004, 23: 142-145. 10.1183/09031936.03.00070303.PubMedCrossRef
23.
Zurück zum Zitat Guillem P, Billeret V, Buisine MP: Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer. 2000, 88: 856-861. 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D.PubMedCrossRef Guillem P, Billeret V, Buisine MP: Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer. 2000, 88: 856-861. 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D.PubMedCrossRef
24.
Zurück zum Zitat Busso N, Karababa M, Nobile M: Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE. 2008, 3: e2267-10.1371/journal.pone.0002267.PubMedPubMedCentralCrossRef Busso N, Karababa M, Nobile M: Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE. 2008, 3: e2267-10.1371/journal.pone.0002267.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Van Gool F, Gallí M, Gueydan C: Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009, 15: 206-210. 10.1038/nm.1906.PubMedPubMedCentralCrossRef Van Gool F, Gallí M, Gueydan C: Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009, 15: 206-210. 10.1038/nm.1906.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Rongvaux A, Galli M, Denanglaire S: Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008, 181: 4685-4695.PubMedCrossRef Rongvaux A, Galli M, Denanglaire S: Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008, 181: 4685-4695.PubMedCrossRef
27.
Zurück zum Zitat Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994, 14: 1431-1437.PubMedPubMedCentralCrossRef Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994, 14: 1431-1437.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Li J, Hoyle GW: Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells. Dev Biol. 2001, 239: 338-349. 10.1006/dbio.2001.0441.PubMedCrossRef Li J, Hoyle GW: Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells. Dev Biol. 2001, 239: 338-349. 10.1006/dbio.2001.0441.PubMedCrossRef
29.
Zurück zum Zitat Gowan SE, Grossmann RE, Kimani PW: Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. Anat Rec (Hoboken). 2008, 291: 1649-1661.CrossRef Gowan SE, Grossmann RE, Kimani PW: Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. Anat Rec (Hoboken). 2008, 291: 1649-1661.CrossRef
30.
Zurück zum Zitat Aizawa K, Suzuki T, Kada N: Regulation of platelet-derived growth factor-A chain by Krüppel-like factor 5: new pathway of cooperative activation with nuclear factor-kappaB. J Biol Chem. 2004, 279: 70-76. 10.1074/jbc.M306621200.PubMedCrossRef Aizawa K, Suzuki T, Kada N: Regulation of platelet-derived growth factor-A chain by Krüppel-like factor 5: new pathway of cooperative activation with nuclear factor-kappaB. J Biol Chem. 2004, 279: 70-76. 10.1074/jbc.M306621200.PubMedCrossRef
31.
Zurück zum Zitat Budinger GR, Chandel NS, Donnelly HK: Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury. Intensive Care Med. 2005, 31: 121-128. 10.1007/s00134-004-2503-2.PubMedCrossRef Budinger GR, Chandel NS, Donnelly HK: Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury. Intensive Care Med. 2005, 31: 121-128. 10.1007/s00134-004-2503-2.PubMedCrossRef
32.
Zurück zum Zitat Fahy RJ, Lichtenberger F, McKeegan CB: The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol. 2003, 28: 499-503. 10.1165/rcmb.2002-0092OC.PubMedCrossRef Fahy RJ, Lichtenberger F, McKeegan CB: The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol. 2003, 28: 499-503. 10.1165/rcmb.2002-0092OC.PubMedCrossRef
33.
Zurück zum Zitat Wu HP, Chen CK, Chung K: Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc. 2009, 108: 20-27. 10.1016/S0929-6646(09)60028-0.PubMedCrossRef Wu HP, Chen CK, Chung K: Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc. 2009, 108: 20-27. 10.1016/S0929-6646(09)60028-0.PubMedCrossRef
34.
Zurück zum Zitat Ware LB: Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med. 2005, 33: S217-222. 10.1097/01.CCM.0000155788.39101.7E.PubMedCrossRef Ware LB: Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med. 2005, 33: S217-222. 10.1097/01.CCM.0000155788.39101.7E.PubMedCrossRef
35.
Zurück zum Zitat Russell J: Genetics of coagulation factors in acute lung injury. Crit Care Med. 2003, 31: S243-7. 10.1097/01.CCM.0000057870.61079.3E.PubMedCrossRef Russell J: Genetics of coagulation factors in acute lung injury. Crit Care Med. 2003, 31: S243-7. 10.1097/01.CCM.0000057870.61079.3E.PubMedCrossRef
36.
Zurück zum Zitat Hamacher J, Lucas R, Lijnen HR: Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002, 166: 651-656. 10.1164/rccm.2109004.PubMedCrossRef Hamacher J, Lucas R, Lijnen HR: Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002, 166: 651-656. 10.1164/rccm.2109004.PubMedCrossRef
37.
Zurück zum Zitat Ware LB, Conner ER, Matthay MA: von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med. 2001, 29: 2325-2331. 10.1097/00003246-200112000-00016.PubMedCrossRef Ware LB, Conner ER, Matthay MA: von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med. 2001, 29: 2325-2331. 10.1097/00003246-200112000-00016.PubMedCrossRef
38.
Zurück zum Zitat Flori HR, Ware LB, Milet M: Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med. 2007, 8: 96-101. 10.1097/01.PCC.0000257097.42640.6F.PubMedPubMedCentralCrossRef Flori HR, Ware LB, Milet M: Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med. 2007, 8: 96-101. 10.1097/01.PCC.0000257097.42640.6F.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat García-Fernández N, Montes R, Purroy A: Hemostatic disturbances in patients with systemic inflammatory response syndrome (SIRS) and associated acute renal failure (ARF). Thromb Res. 2000, 100: 19-25. 10.1016/S0049-3848(00)00306-6.PubMedCrossRef García-Fernández N, Montes R, Purroy A: Hemostatic disturbances in patients with systemic inflammatory response syndrome (SIRS) and associated acute renal failure (ARF). Thromb Res. 2000, 100: 19-25. 10.1016/S0049-3848(00)00306-6.PubMedCrossRef
40.
Zurück zum Zitat Fujihashi K, Kono Y, Kiyono H: Effect of IL6 on B cells in mucosal immune response and inflammation. Res Immunol. 1992, 143 (7): 744-749. 10.1016/0923-2494(92)80015-D.PubMedCrossRef Fujihashi K, Kono Y, Kiyono H: Effect of IL6 on B cells in mucosal immune response and inflammation. Res Immunol. 1992, 143 (7): 744-749. 10.1016/0923-2494(92)80015-D.PubMedCrossRef
41.
Zurück zum Zitat Bernard GR, Artigas A, Brigham KL: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149: 818-824.PubMedCrossRef Bernard GR, Artigas A, Brigham KL: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149: 818-824.PubMedCrossRef
42.
Zurück zum Zitat Bones RC, Balk RA, Cerra FB: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRef Bones RC, Balk RA, Cerra FB: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRef
43.
Zurück zum Zitat Miura N, Shiota G, Nakagawa T: Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003, 64: 430-434. 10.1159/000070303.PubMedCrossRef Miura N, Shiota G, Nakagawa T: Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003, 64: 430-434. 10.1159/000070303.PubMedCrossRef
44.
Zurück zum Zitat Miura N, Maeda Y, Kanbe T: Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005, 11: 3205-3209. 10.1158/1078-0432.CCR-04-1487.PubMedCrossRef Miura N, Maeda Y, Kanbe T: Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005, 11: 3205-3209. 10.1158/1078-0432.CCR-04-1487.PubMedCrossRef
45.
Zurück zum Zitat Miura N, Nakamura H, Sato R: Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006, 97: 1366-1373. 10.1111/j.1349-7006.2006.00342.x.PubMedCrossRef Miura N, Nakamura H, Sato R: Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006, 97: 1366-1373. 10.1111/j.1349-7006.2006.00342.x.PubMedCrossRef
46.
Zurück zum Zitat Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.PubMedCrossRef Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.PubMedCrossRef
47.
Zurück zum Zitat Vincent J, Ferreira F, Moreno R: Scoring systems for assessing organ dysfunction and survival. Crit Care Clin. 2000, 16: 353-366. 10.1016/S0749-0704(05)70114-7.PubMedCrossRef Vincent J, Ferreira F, Moreno R: Scoring systems for assessing organ dysfunction and survival. Crit Care Clin. 2000, 16: 353-366. 10.1016/S0749-0704(05)70114-7.PubMedCrossRef
48.
Zurück zum Zitat Wright CD, Kucharczuk JC, O'Brien SM: Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model; Society of Thoracic Surgeons General Thoracic Surgery Database. J Thorac Cardiovasc Surg. 2009, 137 (3): 587-595. 10.1016/j.jtcvs.2008.11.042.PubMedCrossRef Wright CD, Kucharczuk JC, O'Brien SM: Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model; Society of Thoracic Surgeons General Thoracic Surgery Database. J Thorac Cardiovasc Surg. 2009, 137 (3): 587-595. 10.1016/j.jtcvs.2008.11.042.PubMedCrossRef
49.
Zurück zum Zitat Vincent Jean-Louis, Rello Jordi, Marshall John: International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302: 2323-2329. 10.1001/jama.2009.1754.PubMedCrossRef Vincent Jean-Louis, Rello Jordi, Marshall John: International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302: 2323-2329. 10.1001/jama.2009.1754.PubMedCrossRef
50.
Zurück zum Zitat Urschel JD: Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg. 1995, 169 (6): 634-40. 10.1016/S0002-9610(99)80238-4.PubMedCrossRef Urschel JD: Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg. 1995, 169 (6): 634-40. 10.1016/S0002-9610(99)80238-4.PubMedCrossRef
51.
Zurück zum Zitat Bouadma Lila, Luyt Charles-Edouard, Tubach Florence: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet. 2010, 375: 463-474. 10.1016/S0140-6736(09)61879-1.PubMedCrossRef Bouadma Lila, Luyt Charles-Edouard, Tubach Florence: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet. 2010, 375: 463-474. 10.1016/S0140-6736(09)61879-1.PubMedCrossRef
Metadaten
Titel
Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study
verfasst von
Shunsaku Takahashi
Norimasa Miura
Tomomi Harada
ZhongZhi Wang
Xinhui Wang
Hideyuki Tsubokura
Yoshiaki Oshima
Junichi Hasegawa
Yoshimi Inagaki
Goshi Shiota
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2010
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-103

Weitere Artikel der Ausgabe 1/2010

Journal of Translational Medicine 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.